Merck & Co.'s earnings call showed robust progress, especially with the advancements in their pipeline, particularly luspatercept, which has shown promising results and is poised for regulatory approval. Anticipated regulatory filings for key product launches, especially in luspatercept, coupled with strong collaboration results with Celgene, are likely to bolster investor confidence. Given the forward-looking statements about substantial market potentials and upcoming regulatory submissions, there appears to be a positive short-term impact on the stock as investors may react optimistically to the company's growth prospects.

[1]